For US health care professionals
Review progression-free survival data.
Learn about the FASLODEX 500-mg dosing schedule and administration.
FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Please see full Prescribing Information.
This product information is intended for US health care professionals only.
FASLODEX is a registered trademark of the AstraZeneca group of companies.
©2011 AstraZeneca. All rights reserved. 1961800 7/12